Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium

Standard

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. / Aust, Stefanie; Bachmayr-Heyda, Anna; Pateisky, Petra; Tong, Dan; Darb-Esfahani, Silvia; Denkert, Carsten; Chekerov, Radoslav; Sehouli, Jalid; Mahner, Sven; Van Gorp, Toon; Vergote, Ignace; Speiser, Paul; Horvat, Reinhard; Zeillinger, Robert; Pils, Dietmar.

in: MOL CANCER, Jahrgang 11, 01.01.2012, S. 69.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

Aust, S, Bachmayr-Heyda, A, Pateisky, P, Tong, D, Darb-Esfahani, S, Denkert, C, Chekerov, R, Sehouli, J, Mahner, S, Van Gorp, T, Vergote, I, Speiser, P, Horvat, R, Zeillinger, R & Pils, D 2012, 'Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium', MOL CANCER, Jg. 11, S. 69. https://doi.org/10.1186/1476-4598-11-69

APA

Aust, S., Bachmayr-Heyda, A., Pateisky, P., Tong, D., Darb-Esfahani, S., Denkert, C., Chekerov, R., Sehouli, J., Mahner, S., Van Gorp, T., Vergote, I., Speiser, P., Horvat, R., Zeillinger, R., & Pils, D. (2012). Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium. MOL CANCER, 11, 69. https://doi.org/10.1186/1476-4598-11-69

Vancouver

Bibtex

@article{835e52b97d984096908852f74e5a3cae,
title = "Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium",
abstract = "BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival.METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p<0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR=0.41; 95%CI 0.27-0.64).CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target.",
keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Estrogen Receptor alpha, Female, Gene Expression Regulation, Neoplastic, HSP90 Heat-Shock Proteins, Humans, Middle Aged, Neoplasm Staging, Ovarian Neoplasms, Protein Binding, Protein Transport, Treatment Outcome, Young Adult",
author = "Stefanie Aust and Anna Bachmayr-Heyda and Petra Pateisky and Dan Tong and Silvia Darb-Esfahani and Carsten Denkert and Radoslav Chekerov and Jalid Sehouli and Sven Mahner and {Van Gorp}, Toon and Ignace Vergote and Paul Speiser and Reinhard Horvat and Robert Zeillinger and Dietmar Pils",
year = "2012",
month = jan,
day = "1",
doi = "10.1186/1476-4598-11-69",
language = "English",
volume = "11",
pages = "69",
journal = "MOL CANCER",
issn = "1476-4598",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -a study of the OVCAD consortium

AU - Aust, Stefanie

AU - Bachmayr-Heyda, Anna

AU - Pateisky, Petra

AU - Tong, Dan

AU - Darb-Esfahani, Silvia

AU - Denkert, Carsten

AU - Chekerov, Radoslav

AU - Sehouli, Jalid

AU - Mahner, Sven

AU - Van Gorp, Toon

AU - Vergote, Ignace

AU - Speiser, Paul

AU - Horvat, Reinhard

AU - Zeillinger, Robert

AU - Pils, Dietmar

PY - 2012/1/1

Y1 - 2012/1/1

N2 - BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival.METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p<0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR=0.41; 95%CI 0.27-0.64).CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target.

AB - BACKGROUND: The role of the tumor necrosis factor receptor associated protein 1 (TRAP1) - supposed to be involved in protection of cells from apoptosis and oxidative stress - has just started to be investigated in ovarian cancer. TRAP1 has been shown to be estrogen up-regulated in estrogen receptor α (ERα) positive ovarian cancer cells. The clinical impact of TRAP1 is not clear so far and the significance of ERα expression as therapeutic and prognostic marker is still controversial. Therefore, we investigated the importance of TRAP1 together with ERα in regard to clinicopathological parameters, chemotherapy response, and survival.METHODS AND RESULTS: Expressions of TRAP1 and ERα were evaluated by immunohistochemical staining of tissue microarrays comprised of 208 ovarian cancer samples. TRAP1 was highly expressed in 55% and ERα was expressed in 52% of all cases. High TRAP1 expression correlated significantly with ERα (p<0.001) but high TRAP1 expression was also found in 42% of ERα negative cases. High TRAP1 expression correlated significantly with favorable chemotherapy-response (HR = 0.48; 95%CI 0.24-0.96, p=0.037) and showed a significant impact on overall survival (OS) (HR = 0.65; 95%CI 0.43-0.99, p = 0.044). ERα expression was a favorable prognostic factor for OS in univariate and multivariate analyses. Interestingly, the combined pattern (ERα positive and/or TRAP1-high) revealed the strongest independent and significant positive influence on OS (HR=0.41; 95%CI 0.27-0.64).CONCLUSION: Immunohistochemical evaluation of TRAP1 together with ERα provides significant prognostic information. TRAP1 alone is significantly associated with chemotherapy response and overall survival, rendering TRAP1 as interesting scientific and therapeutic target.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Estrogen Receptor alpha

KW - Female

KW - Gene Expression Regulation, Neoplastic

KW - HSP90 Heat-Shock Proteins

KW - Humans

KW - Middle Aged

KW - Neoplasm Staging

KW - Ovarian Neoplasms

KW - Protein Binding

KW - Protein Transport

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1186/1476-4598-11-69

DO - 10.1186/1476-4598-11-69

M3 - SCORING: Journal articles

C2 - 22978347

VL - 11

SP - 69

JO - MOL CANCER

JF - MOL CANCER

SN - 1476-4598

ER -